ReviewAmerican journal of respiratory and critical care medicine2011
A concise review of pulmonary sarcoidosis.
Review in American journal of respiratory and critical care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
184 citing papers in PubMed, 2 syntheses or guidelines pooled it, 527 citations in OpenAlex.
- Diagnostic Performance of Bronchoalveolar Lavage Fluid CD4/CD8 Ratio for Sarcoidosis: A Meta-analysis.EBioMedicine · 2016Pooled it
- Meta-analysis of genetic programs between idiopathic pulmonary fibrosis and sarcoidosis.PloS one · 2013Pooled it
- Sarcoidosis extent relates to molecular variability.Clinical and experimental immunology · 2017Trial
- Rituximab in the treatment of refractory pulmonary sarcoidosis.The European respiratory journal · 2014Trial
- Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2014Trial
- Sarcoidosis treatment with antifungal medication: a follow-up.Pulmonary medicine · 2014Trial
- Analysis of CCR2 gene variants in patients with sarcoidosis using targeted next-generation sequencing: a case-control study.Molecular biology reports · 2026Article
- Epidemiology and demographic trends of sarcoidosis in southern West Bank, Palestine: a retrospective study (2019-2024).BMC public health · 2026Observational
- Unilateral Panuveitis Secondary to Toxoplasmosis in an Immunocompromised Patient: A Case Report.Cureus · 2026Article
- Optimizing Perioperative Management of Sarcoidosis in Noncardiac Surgery: A Focused Review and Practical Framework.Anesthesiology · 2026Article
- Sarcoidosis With Muscular and Peripheral Nervous System Involvement: An Atypical Presentation of a Rare Disease.Cureus · 2026Article
- Nephrolithiasis in sarcoidosis: epidemiology, risk factors, and clinical implications.World journal of urology · 2026Article
- Sarcoidosis and Obstructive Sleep Apnoea: An Intriguing Relationship.The open respiratory medicine journal · 2026Review
- Gut microbiota and sarcoidosis: a concise review.Frontiers in medicine · 2026Review
- Expert intuition vs. Algorithmic clustering: Mapping radiological subtypes in pulmonary sarcoidosis.PloS one · 2026Article
- Asthma in Patients With Confirmed Pulmonary Sarcoidosis.Canadian respiratory journal · 2026Review
- Probable Renal-Limited Sarcoidosis Presenting With Tubulointerstitial Nephritis Without Granulomas on Renal Biopsy:Sultan Qaboos University medical journal · 2026Article
- Bioinformatics analysis identifies candidate biomarkers associated with sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Signal regulating proteins (SIRPs) participate in sarcoidosis granuloma formation by promoting immune cell aggregation.Respiratory research · 2025Article
- Isolated Optic Neuritis as the Presenting Feature of Neurosarcoidosis: A Case Report and Diagnostic Approach.Cureus · 2025Article
124 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
This is an update on sarcoidosis, focusing on etiology, diagnosis, and treatment. In the area of etiopathogenesis, we now have a better understanding of the immune response that leads to the disease as well as genetic factors that modify both the risk for the disease and its clinical outcome. Several groups have also identified possible agents as a cause for sarcoidosis. Although none of these potential causes has been definitely confirmed, there is increasing evidence to support that one or more infectious agents may cause sarcoidosis, although this organism may no longer be viable in the patient. The diagnosis of sarcoidosis has been significantly aided by new technology. This includes the endobronchial ultrasound, which has been shown to increase the yield of needle aspiration of mediastinal and hilar lymph nodes. The positive emission tomography scan has proven useful for selecting possible biopsy sites by identifying organ involvement not appreciated by routine methodology. It has also helped in assessing cardiac involvement. The biologic agents, such as the anti-tumor necrosis factor antibodies, have changed the approach to refractory sarcoidosis. There is increasing evidence that the clinician can identify which patient is most likely to benefit from such therapy. As new and more potent antiinflammatory agents have been developed, it is clear that there are other factors that burden the patient with sarcoidosis, including fatigue and sarcoidosis-associated pulmonary hypertension. There have been several recent studies demonstrating treatment options for these problems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.